David Thomas, PhD, FRACP, The Kinghorn Cancer Centre, Sydney, Australia, discusses the future directions of sarcoma screening. The penetrance of genetic defects in telomere maintenance and chromosome separation is still to be determined, which is crucial for the development of risk prevention strategies. The identification of two key gene mutations could lead to the development of synthetic lethal strategies. Prof. Thomas highlights the need for the inclusion of common variants and structural mutations in the map of genetic variations associated with sarcomas, which is currently being developed. This interview took place at the ESMO Sarcoma and Rare Cancers Congress 2023 in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
